NCT00446368View on ClinicalTrials.gov

Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2008

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

RAD001

Participant will take RAD001 (Everolimus) 10mg by mouth once a day.

Trial Locations (1)

77030

Baylor College of Medicine - Methodist Hospital, Houston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER